Corrigendum: 2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis

• Adam D. Kennedy,
• Kirk L. Pappan,
• Taraka Donti,
• Mauricio R. Delgado,
• Marwan Shinawi,
• Toni S. Pearson,
• Seema R. Lalani,
• William J. Craigen,
• V. Reid Sutton,
• Anne M. Evans,
• Qin Sun,
• Lisa T. Emrick,
• Lisa T. Emrick,
• Sarah H. Elsea

Affiliations

Adam D. Kennedy

Metabolon, Inc., Morrisville, NC, United States

Kirk L. Pappan

Metabolon, Inc., Morrisville, NC, United States

Taraka Donti

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States

Mauricio R. Delgado

Department of Neurology and Neurotherapeutics, Texas Scottish Rite Hospital for Children, The University of Texas Southwestern Medical Center, Dallas, TX, United States

Marwan Shinawi

Department of Pediatrics, Washington University School of Medicine St. Louis, St. Louis, MO, United States

Toni S. Pearson

Department of Neurology, Washington University School of Medicine St. Louis, St. Louis, MO, United States

Seema R. Lalani

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States

William J. Craigen

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States

V. Reid Sutton

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States

Anne M. Evans

Metabolon, Inc., Morrisville, NC, United States

Qin Sun

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States

Lisa T. Emrick

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States

Lisa T. Emrick

Department of Neurology, Baylor College of Medicine, Houston, TX, United States

Sarah H. Elsea

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States